Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

CVS faces a new lawsuit over its pharmacy networks for HIV/AIDS patients. Photo: RJ Sangosti / The Denver Post via Getty Images

Several HIV/AIDS patients have sued CVS Health, alleging the pharmacy giant flouted federal and state insurance laws by forcing patients into two options: fill their prescriptions at CVS locations or through CVS' mail order, or face thousands of dollars in out-of-pocket costs.

The big picture: It's another lawsuit that raises questions about how people with Aetna health insurance, especially those with expensive chronic conditions, would be treated if CVS got approval to acquire Aetna for $69 billion.

The class-action lawsuit, filed anonymously by patients due to the sensitivity of their conditions, also goes after employers like Amtrak that fund prescription drug plans for their employees and chose to use CVS. The suit boils down to a few key allegations:

  • Patients with a CVS drug plan previously had gone to other local, in-network specialty pharmacies to pick up their HIV/AIDS medications.
  • Patients were shocked to find out their old pharmacy was out-of-network, and they were on the hook for their medications, which could easily cost more than $2,000 a month.
  • CVS changed its pharmacy benefits a few years ago by requiring HIV/AIDS patients to either pick their drugs up at a CVS store or get them delivered to their homes, the suit claims.
  • One plaintiff who is not home several days a week said he found his 90-day mail-ordered supply of drugs "baking in the afternoon sun."
  • Patients also weren't comfortable picking up their drugs because many CVS stores lack private areas to ask questions.
  • The plaintiffs said they also weren't able to opt out of CVS' options.

The major question: Other lawsuits have alleged that CVS uses anticompetitive muscle to force business partners to use certain vendors. Would Aetna customers with conditions like HIV be forced to use CVS and cut ties with their old pharmacies at the risk of paying lots of money for prescriptions out of their pockets?

CVS' response: "We have not been served with this complaint and have not had an opportunity to thoroughly review the allegations. However, (CVS') highest priority is assuring patient access to clinically appropriate drugs while managing overall health care costs for our clients. To that end, we offer our clients multiple clinical tools and pharmacy network options targeted at achieving both of these goals."

Go deeper

Trump's assault on Chinese tech left loose ends galore

Illustration: Sarah Grillo/Axios

President Trump's haphazard war on Chinese tech has left the Biden administration with a raft of unfinished business involving efforts to restrict Chinese firms and products in U.S. markets.

Why it matters: The Chinese and American tech industries are joined at the hip in many ways, and that interdependence has shaped decades of prosperity. But now security concerns and economic rivalries are wrenching them apart.

Biden's thin, short path

President Biden has a thin, short path to success in his first six to nine months, top advisers tell Axios. His success, or failure, will dictate whether he can hold off both Republican critics — and activist Democrats who want him to go bigger, faster.

The big picture: Biden has to get vaccinations moving and the stimulus bill pumping, so the economy will start rocking, advisers said. That’s why he loaded his White House with veteran loyalists focused almost exclusively on these two topics.

Most states aren't prioritizing prisons for COVID vaccines

Illustration: Eniola Odetunde/Axios

Most states have not made much of their incarcerated populations eligible for the COVID-19 vaccine.

The big picture: Jails and prisons have seen big outbreaks and a higher death rate than the general public, but with supplies still limited, most governors aren't putting prisoners at the top of the list for vaccines.